Dr. Allison on the Impact of Immunotherapy in Cancer


In Partnership With:

James P. Allison, PhD, discusses the impact of immunotherapy on patients with cancer. 

James P. Allison, PhD, chair, Immunology, executive director, Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, and a recipient of the 2018 Nobel Prize in Physiology or Medicine, discusses the impact of immunotherapy on patients with cancer. 

Immunotherapy is a pillar of cancer treatment and deserves to be recognized as such, Allison says. Moreover, immunotherapy has the potential to be curative as new molecules are developed and investigated as both monotherapies, and in combination with conventional therapies, Allison continues. The magnitude of immuno-oncology is promising, and new developments in the space have the potential to cure many more patients with cancer, Allison concludes. 

Related Videos
Samilia Obeng-Gyasi, MD, MPH
Tycel Phillips, MD
Ajai Chari, MD
Reshma Jagsi, MD, DPhil, Emory University
Nisha A. Mohindra, MD, Northwestern University Feinberg School of Medicine
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Dan S. Childs, MD, medical oncologist, Mayo Clinic
Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.
Jane L. Meisel, MD